Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics

Ruiyi Deng, Boyuan Wang, Mingrui Zou, Kaiyuan Mao, Jiaheng Shang, Jianhui Qiu, Jingcheng Zhou, Hua Xu, Xin Ma, Yizhou Wang, Lin Cai, Kan Gong · 2026

Read Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics by Ruiyi Deng, Boyuan Wang, Mingrui Zou, Kaiyuan Mao, Jiaheng Shang, Jianhui Qiu, Jingcheng Zhou, Hua Xu, Xin Ma, Yizhou Wang, Lin Cai, Kan Gong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13560369.txt.

Description

Ruiyi Deng and co-authors review fresh drug targets tied to the VHL gene, best known for its role in a kidney cancer, in a 2026 paper. The gene's protein tags other proteins for disposal and helps cells sense oxygen. Drugs that block its usual partner have helped some kidney cancer patients, but many tumors never respond or learn to resist.

The review grades proof for new targets that steer cell growth, fuel use, tissue structure, and immune action. It also covers a drug style that borrows the VHL protein itself to destroy cancer drivers once thought undruggable. Most proof still comes from lab and animal work, so the authors flag what trials must settle.

Catalog record

CREATORRuiyi Deng, Boyuan Wang, Mingrui Zou, Kaiyuan Mao, Jiaheng Shang, Jianhui Qiu, Jingcheng Zhou, Hua Xu, Xin Ma, Yizhou Wang, Lin Cai, Kan Gong
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE157 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13560369

Browse the full library · About the Tower of Babel